Predictive Value of Stemness Factor Sox2 in Gastric Cancer Is Associated with Tumor Location and Stage

Lang Yang1*, Jun-Feng Xu1,2*, Qian Kang1a, Ai-Qin Li1, Peng Jin1, Xin Wang1, Yu-Qi He1, Na Li1, Tao Cheng3ab, Jian-Qiu Sheng1*

1 Department of Gastroenterology, PLA Army General Hospital, Beijing, China, 2 Graduate College, PLA General Hospital, Beijing, China, 3 Department of Pathology, PLA Army General Hospital, Beijing, China

* These authors contributed equally to this work.
# Current address: Department of Gastroenterology, PLA Army General Hospital, Dongcheng District, Beijing, China
b Current address: Department of Pathology, PLA Army General Hospital, Dongcheng District, Beijing, China
* jianqiu@263.net (JQS); yanglang2009@126.com (LY)

Abstract

Cancer stem cells (CSCs) are thought to be the "root" of cancer. Although stemness-related factors ALDH1A1 and Sox2 have been used as markers to identify gastric CSCs, the expression pattern and significance of these factors in gastric cancer have not been sufficiently demonstrated. In this study, the expressions of ALDH1A1 and Sox2 were detected by immunohistochemistry in 122 gastric cancer specimens. And the correlation between Sox2 or ALDH1A1 expression and clinicopathological parameters and overall survival data were analyzed. The positive rate of ALDH1A1 expression was 60%, but there was no significant difference between survival rates of ALDH1A1-positive and ALDH1A1-negative patients. Sox2 was expressed in 42% of specimens and was associated with poor prognosis ($P = 0.015$). Stratified analysis showed that Sox2 expression correlated with shorter lifespan only in patients with cardiac gastric cancers ($P = 0.002$) or stage I or II gastric cancers ($P = 0.002$); but not in patients with non-cardiac cancers ($P = 0.556$) or stage III or IV gastric cancers ($P = 0.121$). Analysis on a database cohort validated the correlation between Sox2 expression and poor prognosis in stage II cancer. Also, expression of Sox2 was associated with lymphnode metastasis in patients with cardiac gastric cancer ($P = 0.037$). A multivariate analysis revealed that Sox2 was an independent prognostic factor in cardiac gastric cancer. Our results indicate that predictive value of Sox2 in gastric cancer is associated with cardiac cancer location and with early cancer stages (I and II).

Introduction

Gastric cancer is one of the most common malignancies worldwide, especially in Eastern Asia, Central and Eastern Europe, and South America[1]. Complete resection of the tumor and
adjacent lymphnodes is the only effective curative treatment. Despite the tremendous improvements in surgery and chemotherapy, the five-year survival rate remains low owing to the nature of metastasis and recurrence [2–4].

Recently, the cancer stem cell (CSC) theory has become a highlight of the cancer research field. CSCs have been identified not only in leukemia, but also in solid tumors, including gastric cancer [5–6]. CSCs play important roles in tumor progression and recurrence [7], and provide a potential therapeutic target [8]. In gastric cancer, stem cell related factors ALDH1 and Sox2 were used as markers to identify the gastric CSCs [6, 9–10]. However, the relationship between these factors and patient prognosis remains to be illustrated. Some reports showed that Sox2 expression was associated with poorer overall survival in gastric cancer [11–12]; however, others argued that the expression of Sox2 decreased during gastric carcinogenesis and this was predictive of better survival [13]. However, no significant correlation between Sox2 and survival has been presented [14]. In addition, the predicted prognostic value of ALDH1A1 in gastric cancer remained inconsistent; ALDH1A1 was found to be associated with a poor prognosis of gastric cancer [15], while Wakamatsu et al. demonstrated that ALDH1A1 expression, whether high or low, showed no correlation with survival [16]. Therefore, the role of Sox2 and ALDH1A1 in gastric cancer remains nebulous.

Gastric cancer is a heterogeneous disease that is often reported as a single entity. Topographically, gastric cancer can be classified into cardiac gastric cancer and non-cardiac gastric cancer [17]. In this study, we hypothesized that inconsistency in the published results may be related to stratified pathological factors. Therefore, we evaluated the expression of ALDH1A1 and Sox2 in gastric cancer samples, and, with respect to stratification, analyzed their correlation with pathological parameters and patient survival.

**Materials and Methods**

**Patients and specimens**

A total of 122 Gastric adenocarcinoma tissues were collected from 2010 to 2013 at PLA Army General Hospital (Beijing, China). No preoperative radiotherapy or chemotherapy was performed before surgery for the patients; patients were monitored every three to six months. There were 100 male patients and 22 female patients. The mean age is 63 years (range, 29–82 years). Tumor stage was classified according to the 7th Union International Cancer Control (UICC) TNM staging system. To analyze for stratification based on the tumor location, gastric cancers that meet Siewert type II and III, according to Siewert classification [18], were classified as cardiac gastric cancer, while the rest were classified as non-cardiac gastric cancer. All tissue samples were fixed in 10% neutral formalin and embedded in paraffin. A tissue array was constructed and cut into 4-μm sections. This study was approved by the ethical review committee of PLA Army General Hospital; written informed consent was obtained from each patient.

**Immunohistochemistry**

Immunohistochemistry was performed as described [19]. Briefly, the tissue array section was dehydrated with xylene, rehydrated, pretreated with 3% H2O2, and then was subjected to antigen retrieval. The slides were incubated with mouse anti-human ALDH1A1 (dilution 1:1000; BD Bioscience, USA) or rabbit anti-human Sox2 (dilution 1:200; Cell Signaling Technology, USA) at 4°Covernight. The horseradish peroxidase (HRP) labeled secondary antibody was added for 30 minutes at room temperature. At last, Reactions were revealed with 3, 3′-diaminobenzidine (DAB, Zhongshan Gold Bridge Corporation, China). Slides were then counterstained with hematoxylin, dehydrated with alcohol and xylene, and mounted on cover slips. The Immunohistochemistry results were interpreted as follows [11, 19–20]: briefly, the cells with brown
color in the cytoplasm for ALDH1A1 and nuclei for Sox2 staining were counted as positive cells. At least five fields were randomly selected for calculating average percentage of positive cells over total cancer cells. The sections with less than 5% positive cancer cells were designated as negative and sections with more than 5% positive cancer cells were designated as positive.

Statistical analysis

All data were analyzed with SPSS13.0 statistical software (SPSS Inc. Chicago, IL). The Pearson Chi-square test and Fisher’s exact test were used to evaluate comparisons of clinico-pathological characteristics. Kaplan–Meier survival plots and log-rank statistics were used to compare the survival rates of patients with follow-up data. Multivariate analyses were performed using the Cox proportional hazards regression model. Variables with \( P \) value < 0.05 in univariate analysis were used in the multivariate regression. \( P \) values<0.05 were considered statistically significant.

Results

Expression of Sox2 and ALDH1A1 in gastric cancer

Sox2 was found located in nuclei and ALDH1A1 was stained in cell plasma (Fig 1). Forty-two percent (51/122) of gastric cancer samples showed Sox2 positive expression (Table 1). No correlation was found between Sox2 expression and age (\( P = 0.375 \)), sex(\( P = 0.701 \)), Lauren classification(\( P = 0.623 \)), cardiac cancer(\( P = 0.199 \)), T stage(\( P = 0.430 \)), N stage(\( P = 0.166 \)), TNM stage (\( P = 0.894 \)) or ALDH1A1 expression(\( P = 0.192 \)) in gastric cancer (Table 1). Sixty percent (73/122) of gastric cancer samples showed ALDH1A1 positive expression (S1 Table). The expression of ALDH1A1 was positively correlated with cardiac cancer (\( P = 0.006 \)). No correlation was found between ALDH1A1 expression in gastric cancer and age (\( P = 0.194 \)), sex (\( P = 0.688 \)), Lauren classification(\( P = 0.856 \)), T stage(\( P = 0.050 \)), N stage(\( P = 0.390 \)), or TNM stage(\( P = 0.118 \)) (S1 Table).

Correlations between Sox2 and ALDH1A1 expression and patient survival time

We analyzed how the expression levels of Sox2 and ALDH1A1 individually correlate with overall survival in a total 116 gastric cancer patients with follow-up data. Median survival time of the 116 gastric cancer patients was 26 months (ranging from 1 to 75 months) and Fifty-three percent (62/116) were deceased at this time point. Kaplan–Meier survival curves showed that patients with Sox2 negative tumors had better prognoses compared to those with Sox2 positive tumors (Fig 2A, \( P = 0.015 \)). In addition, similar survival rates were observed regardless of ALDH1A1 positivity (Fig 2B, \( P = 0.172 \)) while patients with negative ALDH1A1 and Sox2 expression has higher survival rate than patients with ALDH1A1 and/or Sox2 positive expression (Fig 2C, \( P = 0.028 \) and S1 Fig). In addition, we also use the database (http://kmplot.com/analysis/) to analyze the relationship between ALDH1A1 and Sox2 mRNA levels and survival of gastric cancer patients; we found that high ALDH1A1 mRNA levels were associated with better survival, while, high Sox2 mRNA levels were associated with poor prognosis (S2 Fig). Moreover, a multivariate analysis revealed that the expression of Sox2, TNM stage and diffuse type histology were independent prognostic factors for overall survival (Table 2).
Predictive value of ALDH1A1 and Sox2 with respect to tumor stage and location

We also analyzed, with respect to stratification, the predictive value of Sox2 and ALDH1A1 expression in relation to stage and location. We found that Sox2 positive expression was associated with shorter survival in overall patients at Stages I and II, but not at Stages III and IV (Fig 3A and S3 Fig). Univariate analysis showed that expression of Sox2 was the only factor associated with prognosis for overall patients with gastric cancer at Stages I and II (Table 3). It is of interest that high Sox2 mRNA levels were associated with poor prognosis in Stage II, but with better survival in Stage III, based on the data from http://kmplot.com/analysis/ (Fig 4).

The predictive value of Sox2 expression in patients with cardiac or non-cardiac gastric cancer was analyzed. We found that patients with Sox2 negative cardiac cancers have better survival than those with Sox2 positive cardiac cancers. However, Sox2 expression status had no bearing on survival rates in non-cardiac gastric cancers (Fig 3B). In addition, the interactions between SOX2 expression and tumor staging or location in relationship to survival were analyzed by using Cox regression model, no interaction was found between Sox2 expression...
and tumor location or staging in relationship to survival (S2 Table). Multivariate analysis revealed that Sox2 expression and diffuse type histology were independent prognostic factors for overall survival in cardiac gastric cancer (Table 2).

Moreover, we analyzed the relationship between Sox2 and clinical parameters in cardiac gastric cancer, and found that Sox2 expression was positively associated with lymph node metastasis (Table 4, \( P = 0.037 \)). There were no associations found between Sox2 expression and age, sex, Lauren classification, invasion depth, and TNM stage in cardiac gastric cancers (Table 4), and there were no associations found between Sox2 expression and the same clinicopathological factors in non-cardiac gastric cancer (S3 Table).

ALDH1A1 expression was not associated with patient survival with respect to tumor stage and location, although it seemed that patients with ALDH1A1 negative non-cardiac cancer had better survival rates than those with ALDH1A1 positive non-cardiac cancers, but there was no statistically significant difference (S4 Fig).

### Discussion

Although rapid progress has been made in basic and translational research on CSCs in the past decade, the precise isolation and identification of CSCs by appropriate experimental methods and markers remains a challenge in the field of CSC research[21]. Gastric CSCs can be isolated or enriched by stem cell specific markers, side-population (SP) phenotypes, or characteristics [22–24] that include spherical growth in conditioned medium[10] and resistance to

| Parameter                  | Total gastric cancer | Sox2 + | Sox2 - | P value |
|----------------------------|----------------------|--------|--------|---------|
| Age (years)                | Total                | Sox2+  | Sox2-  |         |
| ≤60                        | 56                   | 21     | 35     | 0.375   |
| >60                        | 66                   | 30     | 36     |         |
| Sex                        |                      |        |        |         |
| male                       | 100                  | 41     | 59     | 0.701   |
| female                     | 22                   | 10     | 12     |         |
| Lauren classification      |                      |        |        |         |
| intestinal                 | 71                   | 31     | 40     | 0.623   |
| diffuse                    | 51                   | 20     | 31     |         |
| Location                   |                      |        |        |         |
| cardiac                    | 61                   | 29     | 32     | 0.199   |
| non-cardiac                | 61                   | 22     | 39     |         |
| Invasive depth             |                      |        |        |         |
| T1+T2                      | 18                   | 6      | 12     | 0.430   |
| T3+ T4                     | 104                  | 45     | 59     |         |
| Lymph node metastasis      |                      |        |        |         |
| presence                   | 85                   | 39     | 46     | 0.166   |
| absence                    | 37                   | 12     | 25     |         |
| TNM stage                  |                      |        |        |         |
| I+ II                      | 47                   | 20     | 27     | 0.894   |
| III+ IV                    | 75                   | 31     | 44     |         |
| ALDH1A1 expression         |                      |        |        |         |
| negative                   | 49                   | 17     | 32     | 0.192   |
| positive                   | 73                   | 34     | 39     |         |

doi:10.1371/journal.pone.0169124.t001
chemotherapy drugs\cite{25}. ALDH1 activity and Sox2 expression measurements were employed as markers for the isolation and characterization of gastric CSCs\cite{9, 26–29}. However, the association of ALDH1 and Sox2 expression with pathological parameters and patient survival in gastric cancer remains controversial.

A meta-analysis revealed that Sox2 over-expression was associated neither with the overall survival nor with the other clinicopathological factors with obvious heterogeneity\cite{30–31}. In our study, we analyzed the data, with respect to stratification, based on tumor location and

Table 2. Univariate and Multivariate Cox Models for the Association between Survival and Clinicopathological Factors in Patients with Gastric Cancer.

| Variables                      | Univariate Analysis | Multivariate analysis |
|--------------------------------|---------------------|-----------------------|
|                                | Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value |
| Total gastric cancer           |                     |          |                      |        |
| Age (<60 vs. >60 years)        | 1.54(0.93–2.56)     | 0.096     | 2.00(1.17–3.40)     | 0.011 |
| Sex (male vs. female)          | 1.13(0.59–2.17)     | 0.712     | 1.81(0.53–6.21)     | 0.345 |
| Location (cardiac vs. non-cardiac) | 0.93(0.56–1.53) | 0.772 |                      |        |
| Lauren classification (intestinal vs. diffuse) | 2.52(1.51–4.20) | 0.000 | 1.49(0.50–4.41) | 0.476 |
| Invasive depth (T1, T2 vs. T3, T4) | 4.83(1.51–15.43) | 0.008 | 3.15(1.20–8.31) | 0.020 |
| Lymph node metastasis (N0 vs. N1-N3) | 4.88(2.31–10.30) | 0.000 | 1.72(0.35–8.34) | 0.502 |
| TNM stage (I, II vs.III, IV)   | 4.66(2.45–8.86)     | 0.000     | 3.15(1.20–8.31)     | 0.020 |
| ALDH1A1 (negative vs. positive) | 1.20(0.51–2.83)     | 0.676     | 2.44(1.09–5.50)     | 0.031 |
| Sox2 (negative vs. positive)   | 1.83(1.11–3.02)     | 0.017     | 2.02(1.20–3.40)     | 0.008 |
| Cardiac gastric cancer         |                     |          |                      |        |
| Age (<60 vs. >60 years)        | 1.48(0.65–3.34)     | 0.350     |                      |        |
| Sex (male vs. female)          | 1.66(0.62–4.45)     | 0.316     |                      |        |
| Lauren classification (intestinal vs. diffuse) | 4.36(1.98–9.56) | 0.000 | 2.93(1.29–6.67) | 0.011 |
| Invasive depth (T1, T2 vs. T3, T4) | 2.32(0.55–9.81) | 0.253 |                      |        |
| Lymph node metastasis (N0 vs. N1-N3) | 6.76(2.34–19.57) | 0.000 | 1.72(0.35–8.34) | 0.502 |
| TNM stage (I, II vs.III, IV)   | 5.47(2.18–13.69)    | 0.000     | 2.57(0.71–9.39)     | 0.152 |
| ALDH1A1 (negative vs. positive) | 1.20(0.51–2.83)     | 0.676     |                      |        |
| Sox2 (negative vs. positive)   | 3.28(1.50–7.15)     | 0.003     | 2.44(1.09–5.50)     | 0.031 |

doi:10.1371/journal.pone.0169124.t002
Fig 3. Kaplan-Meier survival curves of patients with different stages and tumor locations according to Sox2 expression. (A) Overall survival of patients in the Stage I and II group and in the Stage III and IV group. (B) Overall survival of patients in the cardiac gastric cancer and in non-cardiac cancer groups.

doi:10.1371/journal.pone.0169124.g003

Table 3. Univariate Analysis for the Association between Survival and Clinicopathological Factors in Patients with Gastric Cancer at Stages I and II.

| Variables                                  | Hazard ratio (95% CI) | P value |
|--------------------------------------------|-----------------------|---------|
| Stage I and II                             |                       |         |
| Age (≤60 vs. >60 years)                    | 2.26(0.68–7.51)       | 0.185   |
| Sex (male vs. female)                      | 0.99(0.13–7.64)       | 0.985   |
| Location (cardiac vs. non-cardiac)         | 0.90(0.30–2.81)       | 0.858   |
| Lauren classification (intestinal vs. diffuse) | 2.06(0.65–6.52)       | 0.218   |
| Invasive depth (T1, T2 vs. T3, T4)         | 2.71(0.59–12.39)      | 0.198   |
| Lymph node metastasis (N0 vs. N1-N3)       | 2.56(0.81–8.10)       | 0.109   |
| TNM stage (I vs. II)                       | 4.23(0.55–32.76)      | 0.168   |
| ALDH1A1 (negative vs. positive)             | 0.97(0.31–3.02)       | 0.962   |
| Sox2 (negative vs. positive)               | 6.06(1.63–22.46)      | **0.007** |

doi:10.1371/journal.pone.0169124.t003
stage, we found that Sox2 had predictive value in cardiac gastric cancers or earlier stage (Stages I and II), but not in non-cardiac gastric cancers or later stage (Stages III and IV). The results based on the database also supported the hypothesis that Sox2 expression is associated with a poor prognosis at earlier tumor stages. Our data suggested that tumor location and stage might be factors that have resulted in inconsistent published data.

Adenocarcinoma of esophagogastric junction (AEG) can be divided into three types according to Siewert classification[18]. The Siewert type II AEG and the Siewert type III AEG (which we referred to as cardiac gastric cancer in this paper) are recommended to be considered as gastric cancers[32–33]. The incidence of AEG is increasing in the western countries, while there is no obvious evidence that indicates a rapid increase of AEG in the eastern countries.
however, the proportion of incidence of cardiac cancers to that of total gastric cancers has sharply increased in China[34]. In addition, gastric cardiac cancers (Siewert type II and III) have distinct clinicopathological features and risk factors that clearly differ from those of non-cardiac gastric cancers[17, 35]. Based on our data, the percentage of cardiac cancers may influence the result of predictive value of Sox2 in total gastric cancer.

Sox2 is a transcription factor that plays an important role in fetal development and in cancer biology[36–37]. Sox2 positive stomach cells possess stem cell properties, and can differentiate into all cell types in both the pylorus and corpus glands[38]. The role of Sox2, however, was shown to be paradoxical in gastric cancer[37]. Sox2 was reported as a tumor suppressor that inhibits cell growth by either regulating cyclin D1, phosphorylated Rb, or p27 (Kip1) levels[39], or directly activating PTEN[13]. In addition, Sox2 has been shown to inhibit migration and invasion by upregulating p21 expression in gastric cancer[40]. However, others demonstrated that Sox2 operates as an oncogene in gastric cancer. Blocking Sox2 has been shown to reduce gastric cancer cell proliferation, migration, and tumorigenic potential[41], and impair the cancer stem cell like phenotype[42]. In our study, we found that Sox2 was associated with lymphnode metastasis in gastric cardiac cancer (Siewert type II and III); however, the exact mechanism by which Sox2 correlated with poor survival in cardiac gastric cancer but not with non-cardiac gastric cancer needs further research.

ALDH1 is a predominant isoform of aldehyde dehydrogenase, which participates in the metabolism of a wide variety of aliphatic and aromatic aldehydes[43–44].

Table 4. The Relationship between Sox2 and Clinicopathological Parameter in Cardiac Gastric Cancer.

| Parameter                        | Cardiac gastric cancer (N) | P value |
|----------------------------------|---------------------------|---------|
|                                  | Total | Sox2+ | Sox2- |       |
| **Age (years)**                  |       |       |       |       |
| ≤60                              | 21    | 9     | 12    | 0.596 |
| >60                              | 40    | 20    | 20    |        |
| **Sex**                          |       |       |       |       |
| male                             | 51    | 25    | 26    | 0.735a|
| female                           | 10    | 4     | 6     |        |
| **Lauren classification**        |       |       |       |       |
| intestinal                       | 37    | 17    | 20    | 0.757 |
| diffuse                          | 24    | 12    | 12    |        |
| **Invasive depth**               |       |       |       |       |
| T1+ T2                           | 7     | 1     | 6     | 0.106a|
| T3+ T4                           | 54    | 28    | 26    |        |
| **Lymph node metastasis**        |       |       |       |       |
| presence                         | 38    | 22    | 16    | 0.037 |
| absence                          | 23    | 7     | 16    |        |
| **TNM stage**                    |       |       |       |       |
| I+ II                            | 26    | 10    | 16    | 0.221 |
| III+ IV                          | 35    | 19    | 16    |        |
| **ALDH1A1 expression**           |       |       |       |       |
| negative                         | 17    | 7     | 10    | 0.536 |
| positive                         | 44    | 22    | 22    |        |

* Fisher’s exact test

doi:10.1371/journal.pone.0169124.t004
cancer cells with high ALDH1 actively possess CSC properties was reported in various tumor types including breast cancer[45], esophageal squamous cell cancer[19], colon cancer[46], lung cancer [47], and gastric cancer[9, 26]. However, the expression and significance of ALDH1A1 in gastric cancer is still unclear. Shen et al. found that ALDH1A1 mRNA was downregulated in gastric cancer and that high ALDH1A1 mRNA level was associated with better overall survival in gastric cancer patients, and was predictive of better survival in gastric intestinal type cancer, but not in diffuse type cancer[48]. Wakamatsu et al. found ALDH1 positivity to be significantly higher in T stage and TNM stage; however, this result did not correlate with any prognostic impact[16]. Li et al. reported that ALDH1A1 was an independent prognostic factor for both overall survival and recurrence-free survival[15]. In our study, we found that ALDH1A1 positive expression was neither associated with survival data nor with clinicopathological factors except for cardiac cancer location.

This study is limited owing to its small cohort size. Predictive survival in relation to Sox2 expression could not be addressed with respect to each TNM stage.

In conclusion, we found that positive Sox2 expression was associated with worse survival in patients with cardiac gastric cancer and earlier cancer stages (Stages I and II). Tumor location and stage may be important factors involved in gastric cancer heterogeneity, and should be considered in future studies.

Supporting Information

S1 Fig. Kaplan-Meier survival curves of patients with gastric cancer according to the joint expression of Sox2 and ALDH1A1.

(TIFF)

S2 Fig. The prognostic value of mRNA level of ALDH1A1 and Sox2 in all gastric cancer patients assessed by the Kaplan-Meier plotter. (A) ALDH1A1 (212224_at); (B) Sox2 (228038_at).

(TIFF)

S3 Fig. Kaplan-Meier survival curves of patients with stage III gastric cancer according to Sox2 expression.

(TIFF)

S4 Fig. Kaplan-Meier survival curves of patients with different stages and tumor locations associated with ALDH1A1 expression. (A) Overall survival of patients in the Stage I and II group and in the Stage III and IV group. (B) Overall survival of patients in the cardiac gastric cancer and in non-cardiac cancer groups.

(TIFF)

S1 Table. The Relationship between ALDH1A1 and Clinicopathological Parameter in Total Gastric Cancer.

(DO CX)

S2 Table. Cox Regression Model for the Interactions between SOX2 Expression and Location or Staging Adjusting for Age and Sex.

(DO CX)

S3 Table. The Relationship between Sox2 and Clinicopathological Parameter in Non-Cardiac Gastric Cancer.

(DO CX)
Acknowledgments

We thank Professor You-Hong Cui from the Department of Pathology, Southwest Hospital, Third Military Medical University, Chongqing, China, for critical review of the manuscript. We thank associate professor Zhi-Wen Li from Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, China, for assistance in statistics.

Author Contributions

Conceptualization: LY JQS.
Data curation: LY.
Formal analysis: LY QK PJ YQH.
Funding acquisition: LY.
Investigation: LY JFX AQL XW NL.
Methodology: LY JFX.
Project administration: LY.
Resources: AQL XW NL TC.
Software: LY JFX.
Supervision: JQS.
Validation: LY JFX TC.
Visualization: JFX.
Writing – original draft: LY.
Writing – review & editing: JQS.

References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87–108. doi: 10.3322/caac.21262 PMID: 25651787
2. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006; 12(3):354–362. doi: 10.3748/wjg.v12.i3.354 PMID: 16489633
3. Dechaphunkul A, Mulder K, El-Gehani F, Ghosh S, Deschenes J, Spratlin J. Clinicopathologic characteristics and survival outcomes of patients with advanced esophageal, gastroesophageal junction, and gastric adenocarcinoma: a single-institution experience. Curr Oncol. 2012; 19(6):302–307. doi: 10.3747/co.19.1081 PMID: 23300355
4. Shiraishi N, Sato K, Yasuda K, Inomata M, Kitano S. Multivariate prognostic study on large gastric cancer. J Surg Oncol. 2007; 96(1):14–18. doi: 10.1002/jso.20631 PMID: 17582596
5. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumors: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008; 8(10):755–768. doi: 10.1038/nrc2499 PMID: 18784658
6. Brungs D, Aghmesheh M, Vine KL, Becker TM, Carolan MG, Ranson M. Gastric cancer stem cells: evidence, potential markers, and clinical implications. J Gastroenterol. 2016; 51(4):313–326. doi: 10.1007/s00535-015-1125-5 PMID: 26428661
7. Patel P, Chen EJ. Cancer stem cells, tumor dormancy, and metastasis. Front Endocrinol (Lausanne). 2012; 3:125. Epub 2012/10/31.
8. Zhang GF, Li CX, Liu ZQ, Ma S, Chen HB. Cancer stem cell targets—a review. Eur Rev Med Pharmacol Sci. 2016; 20(10):2045–2051. PMID: 27249603
9. Katsuno Y, Ehata S, Yashiro M, Yanagihara K, Hirakawa K, Miyazono K. Coordinated expression of REG4 and aldehyde dehydrogenase 1 regulating tumourigenic capacity of diffuse-type gastric carcinoma-initiating cells is inhibited by TGF-beta. J Pathol. 2012; 228(3):391–404. doi: 10.1002/path.4020 PMID: 22430847

10. Yang L, Ping YF, Yu X, Qian F, Guo ZJ, Qian C, et al. Gastric cancer stem-like cells possess higher capability of invasion and metastasis in association with a mesenchymal transition phenotype. Cancer Lett. 2011; 310(1):46–52. doi: 10.1016/j.canlet.2011.06.003 PMID: 21782323

11. Camilo V, Barros R, Celestino R, Castro P, Vieira J, Teixeira MR, et al. Immunohistochemical molecular phenotypes of gastric cancer based on SOX2 and CDX2 predict patient outcome. BMC Cancer. 2014; 14:753. Epub 2014/10/11. doi: 10.1186/1471-2407-14-753 PMID: 25300947

12. Matsuoka J, Yashiro M, Sakurai K, Kubo N, Tanaka H, Muguruma K, et al. Role of the stemness factors sox2, oct3/4, and nanog in gastric carcinoma. J Surg Res. 2014; 174(1):130–5. doi: 10.1016/j.jss.2010.11.903 PMID: 21227461

13. Wang S, Tie J, Wang R, Hu F, Gao L, Wang W, et al. SOX2, a predictor of survival in gastric cancer, inhibits cell proliferation and metastasis by regulating PTEN. Cancer Lett. 2015; 358(2):210–219. doi: 10.1016/j.cmlet.2014.12.045 PMID: 25543086

14. Li N, Deng W, Ma J, Wei B, Guo K, Shen W, et al. Prognostic evaluation of Nanog, Oct4, Sox2, PCNA, Ki67 and E-cadherin expression in gastric cancer. Med Oncol. 2015; 32(1):433. Epub 2014/12/11. doi: 10.1007/s12032-014-0433-6 PMID: 25491144

15. Li XS, Xu Q, Fu XY, Luo WS. ALDH1A1 overexpression is associated with the progression and prognosis in gastric cancer. BMC Cancer. 2014; 14:705. Epub 2014/09/26. doi: 10.1186/1471-2407-14-705 PMID: 25253129

16. Wakamatsu Y, Sakamoto N, Oo HZ, Naito Y, Uraoka N, Anami K, et al. Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer. Pathol Int. 2012; 62(2):112–119. doi: 10.1111/j.1440-1827.2011.02760.x PMID: 22243781

17. Martin-Richard M, Custodio A, Garcia-Giron C, Gravalos C, Gomez C, Jimenez-FONSECA P, et al. Seom guidelines for the treatment of gastric cancer 2015. Clin Transl Oncol. 2015; 17(12):996–1004. doi: 10.1007/s12094-015-1456-y PMID: 26691658

18. Siewert JR, Feith M, Stein HJ. Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographic-anatomic subclassification. J Surg Oncol. 2005; 90(3):139–46; discussion 46. Epub 2005/05/17. doi: 10.1002/jso.20218 PMID: 15895452

19. Yang L, Ren Y, Yu X, Qian F, Bian BS, Xiao HL, et al. ALDH1A1 defines invasive cancer stem-like cells and predicts poor prognosis in patients with esophageal squamous cell carcinoma. Mod Pathol. 2014; 27(5):775–783. doi: 10.1038/modpathol.2013.189 PMID: 24201124

20. Kunju LP, Cookingham C, Toy KA, Chen W, Sabel MS, Kleer CG. EZH2 and ALDH-1 mark breast epithelium at risk for breast cancer development. Mod Pathol. 2011; 24(6):786–793. doi: 10.1038/modpathol.2011.8 PMID: 21399615

21. Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, La Noce M, et al. Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. FASEB J. 2013; 27(1):13–24. doi: 10.1096/fj.12-218222 PMID: 23024375

22. Singh SR. Gastric cancer stem cells: a novel therapeutic target. Cancer Lett. 2013; 338(1):110–119. doi: 10.1016/j.canlet.2013.03.035 PMID: 23583679

23. Stojnev S, Krstic M, Ristic-Petrovic A, Stefanovic V, Hattori T. Gastric cancer stem cells: therapeutic targets. Gastric Cancer. 2014; 17(1):13–25. doi: 10.1007/s10120-013-0254-x PMID: 23563919

24. Li K, Dan Z, Nie YQ. Gastric cancer stem cells in gastric carcinogenesis, progression, prevention and treatment. World J Gastroenterol. 2014; 20(18):5420–5426. doi: 10.3748/wjg.v20.i18.5420 PMID: 24833872

25. Xue Z, Yan H, Li J, Liang S, Cai X, Chen X, et al. Identification of cancer stem cells in vincristine preconditioned SGC7901 gastric cancer cell line. J Cell Biochem. 2012; 113(1):302–312. doi: 10.1002/jcb.23356 PMID: 21913215

26. Nishikawa S, Konno M, Hamabe A, Hasegawa S, Kano Y, Ohta K, et al. Aldehyde dehydrogenase high gastric cancer stem cells are resistant to chemotherapy. Int J Oncol. 2013; 42(4):1437–1442. doi: 10.3892/ijo.2013.1837 PMID: 2340340

27. Nguyen PH, Giraud J, Staedel C, Chambonner L, Dubus P, Chevret E, et al. All-trans retinoic acid targets gastric cancer stem cells and inhibits patient-derived gastric carcinoma tumor growth. Oncogene. 2016; 35(43):5619–5628. doi: 10.1038/onc.2016.87 PMID: 27157616

28. Zhi QM, Chen XH, Ji J, Zhang JN, Li JF, Cai Q, et al. Salinomycin can effectively kill ALDH(high) stem-like cells on gastric cancer. Biomed Pharmacother. 2011; 65(7):509–515. doi: 10.1016/j.biopha.2011.06.006 PMID: 21996439
29. Nishii T, Yashiro M, Shinto O, Sawada T, Ohira M, Hirakawa K. Cancer stem cell-like SP cells have a high adhesion ability to the peritoneum in gastric carcinoma. Cancer Sci. 2009; 100(8):1397–1402. doi: 10.1111/j.1349-7006.2009.01211.x PMID: 19493275

30. Lin S, Qi W, Han K, Gan Z, Yao Y, Miu D. Prognostic value of SOX2 in digestive tumors: a meta-analysis. Hepatogastroenterology. 2014; 61(133):1274–1278.

31. Du XM, Wang LH, Chen XW, Li YX, Li YC, Cao YW. Prognostic value of Sox2 expression in digestive tract cancers: A meta-analysis. J Huazhong Univ Sci Technolog Med Sci. 2016; 36(3):305–312. doi: 10.1007/s11596-016-1584-9 PMID: 27376796

32. Huang Q, Shi J, Feng A, Fan X, Zhang L, Mashimo H, et al. Gastric cardiac carcinomas involving the esophagus are more adequately staged as gastric cancers by the 7th edition of the American Joint Commission on Cancer Staging System. Mod Pathol. 2011; 24(1):138–146. doi: 10.1038/modpathol.2010.183 PMID: 20852593

33. Hasegawa S, Yoshikawa T. Adeno carcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies. Gastric Cancer. 2010; 13(2):63–73. doi: 10.1007/s10120-010-0555-2 PMID: 20602191

34. Zhou Y, Zhang Z, Wu J, Ren D, Yan X, Wang Q, et al. A rising trend of gastric cardia cancer in Gansu Province of China. Cancer Lett. 2008; 269(1):18–25. doi: 10.1016/j.canlet.2008.04.013 PMID: 18501504

35. Liou K, Zhang W, Chen X, Yang K, Zhang B, Chen Z, et al. Comparison on Clinicopathological Features and Prognosis Between Esophagogastric Junctional Adenocarcinoma (Siewert II/III Types) and Distal Gastric Adenocarcinoma: Retrospective Cohort Study, a Single Institution, High Volume Experience in China. Medicine (Baltimore). 2015; 94(34):e1386. Epub 2015/08/28.

36. Weina K, Utikal J. SOX2 and cancer: current research and its implications in the clinic. Clin Transl Med. 2014; 3:19. Epub 2014/08/13. doi: 10.1186/2001-1326-3-19 PMID: 25114775

37. Carrasco-Garcia E, Santos JC, Garcia I, Brianti M, Garcia-Puga M, Pedrazzoli J Jr., et al. Paradoxical role of SOX2 in gastric cancer. Am J Cancer Res. 2016; 6(4):701–729. doi: 10.1016/j.stem.2011.09.001 PMID: 21982232

38. Otsubo T, Akiyama Y, Yanagihara K, Yuasa Y. SOX2 is frequently downregulated in gastric cancers and inhibits cell growth through cell-cycle arrest and apoptosis. Br J Cancer. 2008; 98(4):824–831. doi: 10.1038/sj.bjc.6604193 PMID: 18268498

40. Hutz K, Mejias-Luque R, Farsakova K, Ogris M, Krebs S, Anton M, et al. The stem cell factor SOX2 regulates the tumorigenic potential in human gastric cancer cells. Carcinogenesis. 2014; 35(4):942–950. doi: 10.1093/carcin/bgt410 PMID: 24325912

42. Tian T, Zhang Y, Wang S, Zhou J, Xu S. Sox2 enhances the tumorigenicity and chemoresistance of cancer stem-like cells derived from gastric cancer. J Biomed Res. 2012; 26(5):336–345. doi: 10.7555/JBR.26.20120045 PMID: 23554769

45. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007; 1(5):555–67. doi: 10.1016/j.stem.2007.08.014 PMID: 18371393

46. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007; 1(5):555–67. doi: 10.1016/j.stem.2007.08.014 PMID: 18371393

47. Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, Xing L, et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res. 2009; 7(3):330–338. doi: 10.1158/1541-7786.MCR-08-0393 PMID: 19276181

48. Shen JX, Liu J, Li GW, Huang YT, Wu HT. Mining distinct aldehyde dehydrogenase 1 (ALDH1) isoenzymes in gastric cancer. Oncotarget. 2016. Epub 2016/03/26.